SCHEMBL8484589

SCHEMBL8484589

CCCN(CC#CC(C)(O)CCCn1c(=O)c2c(ncn2CCC)n(CC)c1=O)CCC

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 13/20 0.45
▸ PDE4B Q07343 12/20 0.45
▸ PDE4C Q08493 12/20 0.45
▸ PDE4D Q08499 12/20 0.45
▸ ADORA2A P29274 7/20 0.45
▸ ADORA2B P29275 4/20 0.45
▸ CYP1A2 P05177 2/20 0.45
▸ BLM P54132 2/20 0.45
▸ PMP22 Q01453 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ ESR1 P03372 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ NFKB1 P19838 1/20 0.45
▸ ACHE P22303 1/20 0.45
▸ ADORA1 P30542 1/20 0.42
▸ CYP3A4 P08684 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8483332 0.95 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL8483713 0.92 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL8484574 0.90 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL8480234 0.87 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL8482531 0.86 PDE4A (0.56) PDE4APDE4BPDE4CPDE4DADORA2A
Fumaric Acid SCHEMBL8481085 0.85 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DADORA2A
Fumaric Acid SCHEMBL8481075 0.85 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL8480538 0.84 PDE4A (0.57) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL8479184 0.84 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL8479457 0.84 PDE4A (0.56) PDE4APDE4BPDE4CPDE4DADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5965555-A TREATMENT AND/OR PROPHYLAXIS OF CEREBROVASCULAR DISORDERS CHARACTERIZED BY DAMAGE CAUSED BY ISCHEMIA AND SUBSEQUENT NECROTIC DESTRUCTION OF NERVE CELLS(NEURONS) HOECHST AKTIENGESELLSCHAFT (DE) 1999-10-12 — — US disclosed
Send feedback